UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 29, 2013 |
||
HUBEI MINKANG PHARMACEUTICAL LTD. |
||
Nevada |
000-53231 |
26-2410685 |
55 Ubi Ave. 3, #03-01, Mintwell Building |
408864 |
Registrant's telephone number, including area code +65-6747-7883 |
N/A |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CRF 240.13e-4(c))
SECTION 3 - SECURITIES AND TRADING MARKETS
Item 3.02 Unregistered Sales of Equity Securities
On January 29, 2013, we completed a private placement financing involving the sale of 8,011,606 restricted shares of our common stock (each a "Share") to fourteen individuals and one entity at a subscription price of $0.20 per Share for gross proceeds of $1,602,321.20.
In connection with the issuance of the Shares, we relied on the exemption from registration under the United States Securities Act of 1933, as amended, provided by Regulation S, based on representations and warranties provided by the purchasers of the Shares in the subscription agreements entered into between the purchasers and us.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: January 31, 2013
Hubei Minkang Pharmaceutical Ltd. |
||
By: |
|
/s/ Lee Tong Tai |
Name: |
|
Lee Tong Tai |
Title: |
|
President and Director |